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Intrauterine exposure to carbamazepine and specific
congenital malformations: systematic review and case-
control study
Janneke Jentink, research fellow and lecturer in pharmacoepidemiology,1 Helen Dolk, professor of
epidemiology and health services research,2 Maria A Loane, EUROCAT research fellow and lecturer in public
health,2 Joan K Morris, professor of medical statistics,3 Diana Wellesley, clinical geneticist,4 Ester Garne,
consultant paediatrician and EUROCAT perinatal epidemiologist,5 Lolkje de Jong-van den Berg, professor in
pharmacoepidemiology, 1 for the EUROCAT Antiepileptic Study Working Group
ABSTRACT
Objective To identify specific major congenital
malformations associated with use of carbamazepine in
the first trimester of pregnancy.
Design A review of all published cohort studies to identify
key indications and a population based case-control
study to test these indications.
Setting Review of PubMed, Web of Science, and Embase
for papers about carbamazepine exposure in the first
trimester of pregnancy and specific malformations, and
the EUROCAT Antiepileptic Study Database, including
data from 19 European population based congenital
anomaly registries, 1995-2005.
Participants The literature review covered eight cohort
studies of 2680 pregnancies with carbamazepine
monotherapy exposure, and the EUROCAT dataset
included 98075 registrations of malformations covering
over 3.8 million births.
Main outcome measures Overall prevalence for a major
congenital malformation after exposure to
carbamazepine monotherapy in the first trimester. Odds
ratios for malformations with exposure to carbamazepine
among cases (five types of malformation identified in the
literature review) compared with two groups of controls:
other non-chromosomal registrations of malformations
and chromosomal syndromes.
Results The literature review yielded an overall
prevalence for a major congenital malformation of 3.3%
(95% confidence interval 2.7 to 4.2) after exposure to
carbamazepine monotherapy in the first trimester. In 131
registrations of malformations, the fetus had been
exposed to carbamazepine monotherapy. Spina bifida
was the only specific major congenital malformation
significantly associated with exposure to carbamazepine
monotherapy (odds ratio 2.6 (95% confidence interval
1.2 to 5.3) compared with no antiepileptic drug), but the
risk was smaller for carbamazepine than for valproic acid
(0.2, 0.1 to 0.6). There was no evidence for an association
with total anomalous pulmonary venous return (no cases
with carbamazepine exposure), cleft lip (with or without
palate) (0.2, 0.0 to 1.3), diaphragmatic hernia (0.9, 0.1 to
6.6), or hypospadias (0.7, 0.3 to 1.6) compared with no
exposure to antiepileptic drugs. Further exploratory
analysis suggested a higher risk of single ventricle and
atrioventricular septal defect.
Conclusion Carbamazepine teratogenicity is relatively
specific to spina bifida, though the risk is less than with
valproic acid. Despite the large dataset, there was not
enough power to detect moderate risks for some rare
major congenital malformations.
INTRODUCTION
Carbamazepine is one of the most commonly used
antiepileptic drugs in Europe among women of child-
bearing age. Several cohort studies have evaluated the
risk ofmajor congenitalmalformations associatedwith
carbamazepine, and it seemed to be less teratogenic
than valproic acid.1-6 Although around 3000 pregnan-
cies with recorded carbamazepine exposure have been
described in the literature, each individual study on its
own is too small to have the statistical power to detect
risks for specific congenital malformations compared
with other antiepileptic drugs.4 7 8
The EUROCAT (European Surveillance of Conge-
nital Anomalies) Antiepileptic Study Database, which
was set up for a study of lamotrigine, covered 3 881 592
births and contains 131 registrations of malformation
in pregnancy outcomes exposed to carbamazepine
monotherapy, more than in any other published
study.9 This enabled the examination of risks of speci-
fic major congenital malformations associated with
carbamazepine monotherapy.
We reviewed and combined studies on carbamaze-
pine to identify indications of increased risks of specific
malformations after intrauterine exposure to carbama-
zepine monotherapy in the first trimester of preg-
nancy. We tested these indications, or prior
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METHODS
EUROCAT
The EUROCAT Antiepileptic Study Database has
been previously described.6 9 10 It was drawn from 19
population based registries of congenital anomaly in
Europe, covering 3 881 592 births in Europe in 1995-
2005 and 98 075 major congenital malformations:
86 291 non-chromosomal and 11 784 chromosomal.
Information was available for live births, still births or
late fetal deaths from 20weeks’ gestation, and termina-
tions of pregnancy after prenatal diagnosis. The data-
base includes data from registries in Belgium (Antwerp
and Hainaut), Croatia (Zagreb), Denmark (Odense),
France (Paris and Strasbourg), Germany (Mainz and
Saxony-Anhalt), Ireland (Cork and Kerry), Italy (Emi-
liaRomagna andTuscany),Malta,Netherlands (north-
ern part), Norway, Poland (Wielkopolska, rest of
Poland), Spain (Basque Country), Switzerland
(Vaud), and the United Kingdom (Wales).
Literature review
We reviewed PubMed, Web of Science, and Embase
for papers about carbamazepine exposure in the first
trimester of pregnancy and specific malformations
using the following search strategy: ((“Carbamazepi-
ne”[Mesh] OR “antiepileptic drugs”[ti] OR
“AED”[ti]) AND (“Congenital Abnormalities”[Majr]
OR “Pregnancy Complications/drug therapy”[Majr]
OR “birth defects”[ti]) NOT “Clinical Trials, Phase I
as Topic”[Mesh] NOT (“Models, Animal”[Mesh] OR
“Animal Experimentation”[Mesh])) AND “Cohort
Studies”[Mesh] (PubMed n=44) and ‘carbamazepine
and malformation and pregnancy’ (Web of Science
n=141 and Embase n=30). We identified nine cohort
studies that contained a specified case list of all preg-
nancy outcomes with malformation (table 1). 1-5 11-14
We contacted four authors to get more information
about the case list; three were able to supply the infor-
mation requested andwere included,1 3-5 the fourthwas
excluded.1
The eight cohort studies included outcomes of 2680
pregnancies with carbamazepine monotherapy
exposure. Of these, 101 babies had a malformation,
89 of which were classified as major according to
EUROCAT10 andwere classified according to 49 stan-
dard EUROCAT congenital anomaly subgroups. A
case could be counted only once in each subgroup
but could be counted in more than one subgroup.
The 12 cases classified as only minor malformations
according to the EUROCAT classification were
excluded.10 Based on these eight cohorts, the overall
prevalence for a major congenital malformation after
exposure to carbamazepine monotherapy in the first
trimester was 3.3% (95% confidence interval 2.7 to
4.2) (table 1).
The prevalence for specific subgroups of congenital
anomaly was calculated by dividing the subgroup
totals by the total outcomes in pregnancies with carba-
mazepine monotherapy exposure. This prevalence
was compared with the prevalence in the population
covered by the EUROCAT Antiepileptic Study Data-
base (excluding pregnancies with exposure to anti-
epileptic drugs), with χ2 test with Yate’s correction in
S-PLUS7.0. In the combined literature cohort five sub-
groups had a significantly higher prevalence than
expected (P<0.05) (table 2) andwere considered “indi-
cations” to be tested in the case-control study: spina
bifida, total anomalous pulmonary venous return,
cleft lip (with or without palate), diaphragmatic hernia,
and hypospadias.
To check if we missed any indication by concentrat-
ing on published cohort studies in the literature review,
we searched for additional indications in abstracts of
case-control studies. We found one additional indica-
tion for the risk of cleft palate.15 We excluded cleft
palate malformations from our study control group
and examined these registrations separately. Indica-
tions from other case-control studies had all been iden-
tified in the review of cohort studies.
Case-control study
We carried out a population based case-control study
to test the five indications identified in the literature
review. We compared the odds of exposure to
Table 1 | Overview of included cohort studies on effects of carbamazepine taken during pregnancy on congenital
malformations
Study Country Included years
Exposed to carbamazepine monotherapy
Number Malformed Rate (95% CI)
Samrén 199714 Berlin and Magdeburg, Germany; Helsinki, Finland;
Rotterdam, Netherlands; epilepsy institutes
1972-90 280 22 7.9 (5.2 to 11.6)
Diav-Citrin 200111 Israeli Teratogen Information Service Jan 1989-March 1999 108 6 5.6 (2.6 to 11.8)
Kaaja 200312 Finland, Helsinki Jan 1980-Sep 1998 363 10 2.8 (1.5 to 5.0)
Sabers 200413 6 hospitals, Denmark, Sep 1996-May 2000 18 0 0 (0.0 to 17.6)
Wide 20045 Sweden Jul 1995-Dec 2001 703 28 4.0 (2.8 to 5.7)
Meador 20062 25 epilepsy centres, UK and US Oct 1999-Feb 2004 110 5 4.5 (2.0 to 10.2)
Morrow 20063 Pregnancy registry, UK Dec 1996-March 2005 900 20 2.2 (1.4 to 3.4)
Vajda 20074 Pregnancy registry, Australia Jul 1999-Oct 2002 198 10 5.1 (2.8 to 9.0)
Total — 1972-2005 2680 101 3.8 (3.1 to 4.6)
Major according to
EUROCAT*
— — 2680 89 3.3 (2.7 to 4.2)
*According to EUROCAT major congenital malformation classification (based on ICD-10) 12 were only minor malformations and were therefore excluded.
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carbamazepinemonotherapy among each of these five
malformations under study (cases) with the odds of
exposure among two control groups ofmalformations:
a non-chromosomal and a chromosomal control
group. As valproic acid has been shown to be more
teratogenic than other antiepileptic drugs, we com-
pared carbamazepine monotherapy exposure with
“no antiepileptic drug exposure,” “valproic acid
monotherapy,” and “other antiepileptic drug mono-
therapy” (excluding valproic acid).6
Case definition
Cases were defined as all live births, fetal deaths from
20 weeks’ gestation, and terminations of pregnancy
after prenatal diagnosis, non-chromosomal and non-
monogenic, with at least one of the following major
congenital malformations: spina bifida, total anoma-
lous pulmonary venous return, cleft lip (with or with-
out palate), diaphragmatic hernia, and hypospadias.
We excluded all cases of diagnosed monogenic syn-
drome (n=180).
Control definition
Control group 1 included live births, fetal deaths from
20 weeks’ gestation, and terminations of pregnancy
after prenatal diagnosis that involvedmajormalforma-
tions other than the five malformations under study.
Weexcluded chromosomal syndromes aswell as regis-
trations with cleft palate or Pierre Robin sequence
(n=2320) and all anencephaly or encephalocele
(n=1860) to avoid possible misclassification from an
aetiologically similar diagnosis. Five controls were
excluded because of unknown type of birth.
Control group 2 included live births, fetal deaths from
20 weeks’ gestation, and terminations of pregnancy
after prenatal diagnosiswith chromosomal syndromes.
Two controls in this group were excluded because of
unknown type of birth.
Exposure
All registrations with associated maternal use of anti-
epileptic drugs or maternal epilepsy, or both, were
selected, verified by the local registry, and coded by
ATC (Anatomical Therapeutic Chemical Classifica-
tion) code.16 After verification over 99% of all drug
names were known. In 95% of all registrations with
carbamazepine exposure, there was a diagnosis of
maternal epilepsy. To avoid misclassification of expo-
sure we excluded all registrations with an associated
reported diagnosis of maternal epilepsy but without
maternal use of antiepileptic drugs in the first trimester
(42 cases: spina bifida (8), cleft lip (12), diaphragmatic
hernia (5), and hypospadias (17); and 195 controls).
We compared carbamazepine monotherapy in the
first trimester of pregnancy with “no antiepileptic
drug exposure,” “valproic acid monotherapy,” and
“other antiepileptic drug monotherapy excluding val-
proic acid.” In the comparison with valproic acid
monotherapy we excluded from the control group
malformations associated with valproic acid exposure:
atrial septal defect, polydactyly, and craniosynostosis.6
Statistical analyses
Odds ratios were calculated with logistic regression in
Stata. Crude odds ratios were calculated without cor-
rection for any possible confounder and including all
registries even if they had no registration with carba-
mazepine exposure (see appendix 1 on bmj.com).
Odds ratios were adjusted for maternal age (cate-
gorised into <25, 25-29, 30-34, and >34 years) and
year of birth of the child (categorised as before 1999,
1999-2001, and 2002 onwards). If there were sufficient
numbers of cases the adjusted odds ratio was also
corrected for the reporting registry (registries with no
carbamazepine exposure were excluded). No system-
atically recorded information on other potentially
important confounders was available in our dataset.
We also conducted an exploratory analysis to check
if there was evidence in the data of specific malforma-
tions related to carbamazepinemonotherapy that were
not identified by the literature review. We compared
the proportion of each subgroup of specific non-chro-
mosomal congenital anomalies (excluding the five case
groups, but reincluding cleft palate, anencephaly, and
encephalocele) formalformations with carbamazepine
monotherapy exposure with all non-chromosomal
EUROCAT registrations without reported epilepsy
or use of antiepileptic drugs.We compared differences
between proportions with a χ2 test.
RESULTS
In the included study population 516 registered mal-
formationswere in pregnancy outcomeswith recorded
exposure to any antiepileptic drug in the first trimester
of pregnancy, 5.5 per 1000 registrations (516/93 436).
The exposure to antiepileptic drugs was more than
twice as high among the cases (10.9 per 1000 registra-
tions) than among the controls (5.0 and 3.2 per 1000
registrations) (table 3). This difference between cases
and controls was not seen in registered malformations
with any recorded exposure to carbamazepine mono-
therapy. The exposure to carbamazepine monother-
apy was comparable among cases (1.4/1000) and
among non-chromosomal controls (1.5/1000). The
exposure among chromosomal controls was lower
(0.9/1000). The exposure to valproic acid
Table 2 | Result of review of eight cohort studies. All specific malformations found in
literature review were classified to 75 malformation subgroups; 49 subgroups had at least
one case and five (shown here) showed significant increased prevalence compared with




(n=3 869 947) P value†
Anomalous pulmonary venous return 2 (0.75) 134 (0.03) <0.001
Cleft lip, with or without palate 7 (2.61) 3634 (0.94) 0.012
Diaphragmatic hernia 3 (1.12) 766 (0.20) 0.007
Hypospadias 12 (4.48) 5418 (1.40) <0.001
Spina bifida 6 (2.24) 1933 (0.50) <0.001
*Excluding registrations of chromosomal malformations and malformations with reported exposure to
antiepileptic drugs.
†Calculated with χ2 test with Yates’s correction.
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monotherapy was higher among cases than among
both control groups (table 3).
The five case subgroups included 11 790 cases
(table 4). Eighty two cases were included in two differ-
ent subgroups. The control groups consisted of 69 883
non-chromosomalmalformed registrations and11 763
chromosomal registrations.
Carbamazepine monotherapy v no antiepileptic drugs
In the comparison of carbamazepine monotherapy
exposure with no antiepileptic drugs, one of the five
indications found in the literature was confirmed: the
odds ratio for spina bifida was 2.6 (95% confidence
interval 1.2 to 5.3) compared with non-chromosomal
controls and 4.2 (1.5 to 11.2) compared with chromo-
somal controls. The odds ratios for cleft lip (with or
without palate), diaphragmatic hernia, and hypospa-
dias were not appreciably increased; they were all
around or below 1, though for diaphragmatic hernia
the confidence interval was wide. We could not per-
formmeaningful analyses for total anomalous pulmon-
ary venous return because we did not have any cases
with exposure to carbamazepine (table 4).
Carbamazepine monotherapy v other antiepileptic drug
monotherapy
In contrast with the comparison with “no antiepileptic
drugs” the exposure to carbamazepine monotherapy
resulted in a reduced risk for spina bifida compared
with valproic acidmonotherapy, which was significant
in the comparisonwith control group 1 (0.2, 0.1 to 0.6).
Compared with other antiepileptic drug monotherapy
excluding valproic acid, exposure to carbamazepine
monotherapy showed no difference in the risk for
spina bifida (1.1, 0.4 to 3.6).
For hypospadias we found a significantly lower risk
for carbamazepinemonotherapy than for valproic acid
monotherapy (0.2, 0.1 to 0.5) and again no difference
in risk in comparison with other antiepileptic drug
monotherapy excluding valproic acid (0.8, 0.2 to 2.9).
The risk for cleft lip with or without palate was sig-
nificantly lower for carbamazepine monotherapy than
for other antiepileptic drug monotherapy excluding
valproic acid (0.1, 0.0 to 0.6) (over half of these cases
had recorded exposure to phenobarbital). No signifi-
cant difference was seen for carbamazepinemonother-
apy compared with valproic acid monotherapy (0.3,
0.0 to 2.6), but the point estimate was decreased. The
results for diaphragmatic hernia also showed
decreased odds ratios but with wide confidence inter-
vals (table 4).
We tested the one additional indication identified in
literature, cleft palate, in the EUROCAT dataset, but
we did not confirm this indication compared with no
antiepileptic drug exposure (crude odds ratio 1.3 (0.4
to 4.1) with non-chromosomal controls).15
Exploratory analysis
The exploratory analysis of all malformation sub-
groups found that all proportions were similar
(P>0.05) except for two subgroups: single ventricle
(2.3% (n=3) of carbamazepine exposed v 0.3%
expected, χ2 P<0.001) and atrioventricular septal
defect (3.1% (n=4) of carbamazepine exposed v 0.8%
expected, χ2 P<0.011, data available on request).
When we removed registrations with these malforma-
tions from our non-chromosomal control group, our
results regarding the five indication case groups stayed
essentially the same.
DISCUSSION
Interpretation of the results
Of the five indications for specific malformations asso-
ciated with exposure to carbamazepine monotherapy
that we identified from published cohort studies, spina
bifidawas the only confirmed indication (odds ratio 2.6
(1.2 to 5.3) for comparison with no exposure to anti-
epileptic drug and with the non-chromosomal con-
trols). All other case groups resulted in an odds ratio
around or below 1. According to the upper confidence
limits, we could exclude 50%of excess risks for cleft lip
and hypospadias with some degree of certainty, but
further surveillance would be necessary to gain larger
numbers to estimate risks for diaphragmatic hernia
and total anomalous pulmonary venous return with
more precision.
In our analyses comparing exposure to carbamaze-
pinemonotherapywith valproic acidmonotherapywe
found a significantly decreased risk for spina bifida
(odds ratio 0.2, 0.1 to 0.6) and hypospadias (odds
ratio 0.2, 0.1 to 0.5), indicating that the risk of spina
bifida and hypospadias with carbamazepine is less
than with valproic acid. In our study of valproic acid6
we found a sixfold risk for spina bifida and a sevenfold
risk for hypospadias with valproic acid monotherapy
compared with exposure to another antiepileptic drug
with the non-chromosomal control group.
It is noteworthy that the risk for cleft lip with or with-
out palate was significantly more related to other anti-
epileptic drug monotherapy (excluding valproic acid)
than to carbamazepine monotherapy (odds ratio 0.1,
0.0 to 0.6). Over half of these cases were exposed to
Table 3 | Exposure to antiepileptic drugs during pregnancy recorded among registrations of
congenital malformations (cases and controls). Figures are numbers of cases (prevalence per
1000 registrations)
Non-chromosomal cases





Any antiepileptic drug 129 (10.9) 349 (5.0) 38 (3.2)
Any antiepileptic drugmonotherapy 104 (8.8) 282 (4.0) 32 (2.7)
Valproic acid monotherapy 66 (5.6) 102 (1.5) 13 (1.1)
Carbamazepine monotherapy 16 (1.4) 105 (1.5) 10 (0.9)
Other monotherapy 22§ (1.9) 75¶ (1.1) 9** (0.8)
*All cases with anomalous pulmonary venous return, cleft lip (with or without palate), diaphragmatic hernia,
hypospadias, or spina bifida.
†Non-chromosomal malformations, excluding malformations under study.
‡All chromosomal malformations.
§Phenobarbital (9), lamotrigine (5), clonazepam (3), levetriacetam (2), unspecified antiepileptic drugs (3).
¶Lamotrigine (33), phenobarbital (15), oxcarbazepine (10), phenytoin (5), clonazepam (3), primidon (3),
methylphenobarbital (2), topiramate (2), ethosuximide (1), unspecified (1).
**Phenobarbital (4), lamotrigine (2), clonazepam (1), oxcarbamazepine (1), phenytoin (1).
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phenobarbital, which is known to be associated with
cleft lip and palate.17
Comparison with other studies
The rate of major malformation with exposure to car-
bamazepine that we found when combining the eight
cohort studies (3.3%) was lower than the rate reported
in the only meta-analysis in the literature (44/797;
5.5%, 4.1% to 7.3%).18 Eleven of the 16 studies
included in the meta-analysis contained information
about malformations. Three of these 11 presented a
case list with specificmalformations andwere included
in our literature review. The difference in the rate of
malformations could be explained by dissimilarities
in classification of minor malformations for exclusion.
In a general review of the literature, we did not find
any strong suggestions of specific malformations other
thanour five case groups, except for a recently published
abstract based on the North American AED Pregnancy
Registry, which suggested a 24-fold (7.9 to 74.4) increase
in the rate of isolated cleft palate with carbamazepine.15
In theEUROCATdatasetwedidnot confirm this strong
indication, either in the proportional exploratory analy-
sis or by calculation of odds ratios.
Strengths and limitations of the study
One limitation of our study is that we used controls
with malformations. Controls with non-chromosomal
malformations will result in an underestimation of the
effect if there are any individuals left in the control
group with malformations that are related to the expo-
sure. Our exploratory analysis was designed to see if
there were specific malformations of concern; we
found single ventricle and atrioventricular septal
defect to represent a higher proportion than expected
(though this might be a chance finding associated with
multiple comparisons). When we excluded these two
malformations from the control group, our results
stayed essentially the same. Chromosomal controls
can lead to anoverestimation of effect of drug exposure
if exposure is not recorded completely because of the
lack of relevance of drug exposure in early pregnancy.
We have examined this in previous studies of lamotri-
gine and valproic acid69 and found no evidence of sub-
stantially poorer recording of exposure to antiepileptic
drugs for chromosomal controls, either by
examination of exposure rates or by examination of
information gathering procedures for exposure. Expo-
sure information is mainly collected prospectively in
medical records and is ascertained by the registry
regardless of type of malformation. In a previous
study evaluating exposure to valproic acid and specific
congenital malformations, we found similar odds
ratios for non-chromosomal and chromosomal con-
trols, while in our study of lamotrigine exposure and
orofacial clefts, as in the current carbamazepine study,
we found greater odds ratios with chromosomal con-
trols than with non-chromosomal control group. One
interpretation is that there is a generalised risk of mal-
formation associatedwith carbamazepine, which is not
specific to a few malformation groups. With that inter-
pretation, the difference in exposure rate between the
control groupswould suggest an up to 50% generalised
increase risk of major malformations with carbamaze-
pine. Another interpretation is that carbamazepine
“protects” against chromosomal malformations—for
example, by raising the chance of an early miscarriage
for affected pregnancies. In relation to the finding
regarding spina bifida, we consider that the true odds
ratio is likely to be between the estimates obtained
from the two control groups.
The apparent specificity of effect of carbamazepine
for spina bifida, compared with valproic acid, with a
much larger range of effects, might be a useful biologi-
cal clue in elucidating the underlying teratogenic
mechanism. It is also possible that spina bifida is in
part related to the underlying epilepsy rather than the
drug used, though our results show that the drug used
at least affects the level of risk of spina bifida. In this
large population based study, we carried out a direct
comparison between the risks for specific malforma-
tions associated with carbamazepine monotherapy
compared with valproic acid monotherapy. A limita-
tion in our comparison of risks between exposure to
different types of antiepileptic drug was that we did
not have the information to adjust for type of epilepsy,
frequency of seizures, used of folic acid, and dose of the
antiepileptic drug.
Conclusions and policy implications
Although most antiepileptic drugs taken during preg-
nancy significantly increase the risk for one or more
Table 4 | Adjusted* odds ratios (95% confidence intervals) for exposure to carbamazepine monotherapy compared with no antiepileptic drug, valproic acid,
and other antiepileptic drugs, with two control groups: non-chromosomal malformations (control 1) and chromosomal malformations (control 2)
Malformation subgroup (No of cases)
Carbamaze-
pine
No antiepileptic drug Valproic acid monotherapy† Other monotherapy‡
Control 1 Control 2 Control 1 Control 2 Control 1 Control 2
Spina bifida (n=2048) 8 2.6 (1.2 to 5.3) 4.2 (1.5 to 11.2) 0.2 (0.1 to 0.6) 0.3 (0.1 to 1.2) 1.1 (0.4 to3.6) 1.4 (0.3 to 6.6)
Total anomalouspulmonary venous return (n=132) 0 — — — — — —
Cleft lip (with or without palate) (n=3544) 1 0.2 (0.0 to 1.3) 0.2 (0.0 to 1.7) 0.3 (0.0 to 2.6) 0.2 (0.0 to 2.7) 0.1 (0.0 to0.6) 0.0 (0.0 to 0.5)
Diaphragmatic hernia (n=755) 1 0.9 (0.1 to 6.6) 1.0 (0.1 to 8.5) 0.5 (0.0 to 4.5) 0.4 (0.0 to 5.8) 0.2 (0.0 to2.2) 0.2 (0.0 to 2.5)
Hypospadias, boys only (n=5393) 6 0.7 (0.3 to 1.6) 0.5 (0.2 to 1.8) 0.2 (0.1 to 0.5) 0.1 (0.0 to 0.7) 0.8 (0.2 to2.9) 0.4 (0.1 to 4.0)
*Adjusted for year of birth and maternal age. Odds ratios for comparison with no antiepileptic drug additionally adjusted for reporting centre.
†Excluding malformations associated with valproic acid exposure. Cases exposed to valproic acid: spina bifida (27), total anomalous pulmonary venous return (2), cleft lip (3),
diaphragmatic hernia (2), hypospadias (32).
‡Excluding valproic acid. Cases exposed to other antiepileptic drug monotherapy: spina bifida (5), total anomalous pulmonary venous return (0), cleft lip (10), diaphragmatic hernia (3),
hypospadias (5).
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specific fetal malformations, the occurrence of these
malformations is nevertheless rare. Most exposed
pregnancies result in a baby without malformation.
The best option regarding antiepileptic drug treatment
can be chosen only on an individual basis by the
woman and neurologist before pregnancy, weighing
the benefits of epilepsy control against the risk of tera-
togenicity. In this study we have confirmed that carba-
mazepine is less teratogenic than valproic acid. A
Cochrane review found no evidence to support the
belief that valproic acid is superior to carbamazepine
for generalised tonic-clonic seizures.19 Therefore, we
agree with the recent recommendation of the Ameri-
can Academy of Neurology to avoid valproic acid in
pregnancy if possible.20 Our literature review gives a
3.3% risk of major malformations with carbamazepine
monotherapy, and our case-control study shows that
the major concern is a moderately increased risk of
spina bifida. This should to help in decision regarding
whether carbamazepine should be the antiepileptic
drug of choice in pregnancy.
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